LOVFF (Cannara Biotech) Ending Cash Position: $15.90 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LOVFF Cannara Biotech Inc LOVFF
87 GF Score
Price $1.33
GF Value $1.23
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cannara Biotech Ending Cash Position?

Cannara Biotech LOVFF -3.47% 87 Ending Cash Position is $15.90 Mil as of May. 2026. GuruFocus rates LOVFF with a GF Score™ of 87/100 and a GF Value™ of $1.23 (Fairly Valued). The stock has 5 warning signs investors should review.

Cannara Biotech's Ending Cash Position for the quarter that ended in May. 2026 was $15.90 Mil.

Cannara Biotech's quarterly Ending Cash Position increased from Nov. 2025 ($11.75 Mil) to Feb. 2026 ($16.05 Mil) but then declined from Feb. 2026 ($16.05 Mil) to May. 2026 ($15.90 Mil).

Cannara Biotech's annual Ending Cash Position increased from Aug. 2023 ($3.17 Mil) to Aug. 2024 ($4.85 Mil) and increased from Aug. 2024 ($4.85 Mil) to Aug. 2025 ($10.41 Mil).

Cannara Biotech Ending Cash Position Related Terms

Cannara Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Ending Cash Position Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Ending Cash Position
Get a 7-Day Free Trial 6.48 9.38 3.17 4.85 10.41

Cannara Biotech Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.39 10.41 11.75 16.05 15.90
LOVFF
87GF Score
Cannara Biotech Inc LOVFF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cannara Biotech's Ending Cash Position for the fiscal year that ended in Aug. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.8+5.608
=10.41

Cannara Biotech's Ending Cash Position for the quarter that ended in May. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=15.968+-0.068999999999999
=15.90

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $15.90 Mil mean?
Cannara Biotech (LOVFF) has a Ending Cash Position of $15.90 Mil as of May. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Ending Cash Position too high?
Cannara Biotech's current Ending Cash Position is $15.90 Mil. Overall, Cannara Biotech has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Ending Cash Position compare to ZTS?
Cannara Biotech's Ending Cash Position of $15.90 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Ending Cash Position is $15.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.23, compared to a current price of $1.33 — trading 7.9% above its estimated fair value. The current Ending Cash Position is $15.90 Mil. Cannara Biotech's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Ending Cash Position is $15.90 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.33 is trading 7.9% above its estimated GF Value™ of $1.23. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for LOVFF:

  • Ending Cash Position: $15.90 Mil
  • GF Value™: $1.23 vs. price of $1.33 (7.9% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
87GF Score

Get the complete analysis for LOVFF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price
$1.23
GF Value